Syncona's Gyroscope Therapeutics postpones IPO
Syncona portfolio company Gyroscope Therapeutics Holdings has postponed plans for its initial public offering in light of current market conditions, the healthcare firm said on Friday.
"In light of market conditions, we have decided to postpone our planned initial public offering," said Gyroscope Therapeutics chief executive Khurem Farooq.
"Based on the positive feedback we have received from institutional investors on the strength of our science and investigational gene therapies, we believe it's in the best interest of our existing shareholders and employees to execute our IPO in more favourable market conditions.”
“In the meantime, we are continuing to advance our clinical program for our investigational gene therapy, GT005, and our earlier-stage pipeline."